3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Pemetrexed
3
Carboplatin
3
durvalumab
2
Cisplatin
2
tremelimumab
1
repotrectinib
1
pralsetinib
1
osimertinib
1
brigatinib
1
atezolizumab
1
Surgical Procedures, Operative
1
Paclitaxel
1
Mitomycin
1
Gemcitabine
1
Crizotinib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Carcinoma
×
osimertinib
×
Clear all
NCT04035486
2025-10-10
FLAURA2
AstraZeneca
Phase 3
Active not recruiting
587 enrolled
44 charts
1 FDA